The preclinical development of biotechnology-derived pharmaceuticals: the PMA perspective. Pharmaceutical Manufacturers Association.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D005818:Genetic Engineering; D006801:Humans; D011994:Recombinant Proteins / Q000633:toxicity; D012449:Safety; D012957:Societies, Pharmaceutical; D014481:United States
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins